Delayed hypersensitivity to enoxaparin. 1998

R Cabañas, and M T Caballero, and M C López-Serrano, and R Díaz, and J Contreras, and P Barranco, and A Moreno-Ancillo
Allergy Department, Hospital La Paz, Madrid, Spain.

A 65-year-old woman experienced immediate itchy erythematous patches at the subcutaneous injection sites of sodium enoxaparin. An erythematous and infiltrated 40 x 20 mm lesion on the abdominal wall could be observed at the site of enoxaparin injection when she was referred to our clinic 48 h after injection. Lesions subsided spontaneously within 1 week. She had been on this treatment 1 and 3 years before without any adverse reaction. To clarify the nature of the reaction, epicutaneous tests with sodium enoxaparin, calcium nadroparin and calcium heparin were performed, all with negative results. Skin prick test with sodium enoxaparin was also negative. Biopsy of the cutaneous lesion showed spongiotic dermatitis, strongly suggesting a delayed hypersensitivity mechanism. We report here on a new case of delayed hypersensitivity to enoxaparin. Being female, overweight and having prolonged application of the drug were suggested risk factors present in our patient. Biopsy was essential for diagnosis. Although type IV hypersensitivity reactions to enoxaparin are rare, we should start to suspect this condition in order not to underdiagnose it.

UI MeSH Term Description Entries
D006968 Hypersensitivity, Delayed An increased reactivity to specific antigens mediated not by antibodies but by sensitized T CELLS. Hypersensitivity, Tuberculin-Type,Hypersensitivity, Type IV,Tuberculin-Type Hypersensitivity,Type IV Hypersensitivity,Delayed Hypersensitivity,Delayed Hypersensitivities,Hypersensitivity, Tuberculin Type,Tuberculin Type Hypersensitivity,Tuberculin-Type Hypersensitivities,Type IV Hypersensitivities
D007279 Injections, Subcutaneous Forceful administration under the skin of liquid medication, nutrient, or other fluid through a hollow needle piercing the skin. Subcutaneous Injections,Injection, Subcutaneous,Subcutaneous Injection
D010328 Patch Tests Skin tests in which the sensitizer is applied to a patch of cotton cloth or gauze held in place for approximately 48-72 hours. It is used for the elicitation of a contact hypersensitivity reaction. Patch Testing,Patch Test,Patch Testings,Test, Patch,Testing, Patch,Testings, Patch,Tests, Patch
D003875 Drug Eruptions Adverse cutaneous reactions caused by ingestion, parenteral use, or local application of a drug. These may assume various morphologic patterns and produce various types of lesions. Dermatitis Medicamentosa,Dermatitis, Adverse Drug Reaction,Maculopapular Drug Eruption,Maculopapular Exanthem,Morbilliform Drug Reaction,Morbilliform Exanthem,Drug Eruption,Drug Eruption, Maculopapular,Drug Eruptions, Maculopapular,Drug Reaction, Morbilliform,Drug Reactions, Morbilliform,Eruption, Drug,Eruption, Maculopapular Drug,Eruptions, Drug,Eruptions, Maculopapular Drug,Exanthem, Maculopapular,Exanthem, Morbilliform,Exanthems, Maculopapular,Exanthems, Morbilliform,Maculopapular Drug Eruptions,Maculopapular Exanthems,Morbilliform Drug Reactions,Morbilliform Exanthems,Reaction, Morbilliform Drug,Reactions, Morbilliform Drug
D005260 Female Females
D006801 Humans Members of the species Homo sapiens. Homo sapiens,Man (Taxonomy),Human,Man, Modern,Modern Man
D000368 Aged A person 65 years of age or older. For a person older than 79 years, AGED, 80 AND OVER is available. Elderly
D000925 Anticoagulants Agents that prevent BLOOD CLOTTING. Anticoagulant Agent,Anticoagulant Drug,Anticoagulant,Anticoagulant Agents,Anticoagulant Drugs,Anticoagulation Agents,Indirect Thrombin Inhibitors,Agent, Anticoagulant,Agents, Anticoagulant,Agents, Anticoagulation,Drug, Anticoagulant,Drugs, Anticoagulant,Inhibitors, Indirect Thrombin,Thrombin Inhibitors, Indirect
D012867 Skin The outer covering of the body that protects it from the environment. It is composed of the DERMIS and the EPIDERMIS.
D017984 Enoxaparin Low-molecular-weight fragment of heparin, having a 4-enopyranosuronate sodium structure at the non-reducing end of the chain. It is prepared by depolymerization of the benzylic ester of porcine mucosal heparin. Therapeutically, it is used as an antithrombotic agent. (From Merck Index, 11th ed) Clexane,EMT-966,EMT-967,Enoxaparine,Lovenox,PK-10,169,PK-10169,EMT 966,EMT 967,EMT966,EMT967,PK 10,169,PK 10169,PK10,169,PK10169

Related Publications

R Cabañas, and M T Caballero, and M C López-Serrano, and R Díaz, and J Contreras, and P Barranco, and A Moreno-Ancillo
October 1998, Allergy,
R Cabañas, and M T Caballero, and M C López-Serrano, and R Díaz, and J Contreras, and P Barranco, and A Moreno-Ancillo
November 1996, Allergy,
R Cabañas, and M T Caballero, and M C López-Serrano, and R Díaz, and J Contreras, and P Barranco, and A Moreno-Ancillo
January 2013, Semergen,
R Cabañas, and M T Caballero, and M C López-Serrano, and R Díaz, and J Contreras, and P Barranco, and A Moreno-Ancillo
September 2019, Postgraduate medical journal,
R Cabañas, and M T Caballero, and M C López-Serrano, and R Díaz, and J Contreras, and P Barranco, and A Moreno-Ancillo
October 2001, Medicina clinica,
R Cabañas, and M T Caballero, and M C López-Serrano, and R Díaz, and J Contreras, and P Barranco, and A Moreno-Ancillo
February 1996, Allergy,
R Cabañas, and M T Caballero, and M C López-Serrano, and R Díaz, and J Contreras, and P Barranco, and A Moreno-Ancillo
March 2009, Allergy,
R Cabañas, and M T Caballero, and M C López-Serrano, and R Díaz, and J Contreras, and P Barranco, and A Moreno-Ancillo
May 1970, Lancet (London, England),
R Cabañas, and M T Caballero, and M C López-Serrano, and R Díaz, and J Contreras, and P Barranco, and A Moreno-Ancillo
November 1997, Allergy,
R Cabañas, and M T Caballero, and M C López-Serrano, and R Díaz, and J Contreras, and P Barranco, and A Moreno-Ancillo
November 1982, Contact dermatitis,
Copied contents to your clipboard!